Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion - The Seattle Times
Eli Lilly is acquiring three vaccine biotechs in a ~$20B buying spree, including a Seattle-area vaccine maker for $1.5B, as it builds an infectious disease portfolio beyond its GLP-1 franchise. The deals signal LLY is diversifying revenue streams, but the scale of simultaneous acquisitions raises integration risk and near-term cash deployment concerns.
What happened
Eli Lilly is acquiring three vaccine biotechs in a ~$20B buying spree, including a Seattle-area vaccine maker for $1.5B, as it builds an infectious disease portfolio beyond its GLP-1 franchise.
The read · May 27
Fade the LLY pop short-term — $20B+ in simultaneous acquisitions at peak GLP-1 valuation historically pressures acquirer multiples; look to short into the Goldman Healthcare Conference catalyst or wait for a re-entry on pullback to $1,040-$1,050.
Wrong if
If GLP-1 pipeline data or a bullish conference presentation reaffirms the core growth thesis, LLY could squeeze past $1,100+; any positive vaccine efficacy readout from an acquired asset would also invalidate the short.
CoverageSource: Google News · Published here WED, MAY 27 · 9:00 AM ET · the only report in this recordHow this is decided →
The chart · LLYTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
LLY is up 2.1% today on news of a sprawling $20B+ M&A spree across three simultaneous vaccine biotech acquisitions — a scale that typically pressures acquirer multiples as the market reprices integration risk and capital allocation efficiency. Insider data shows 0 buys vs. 2 sells in the last 30 days, a modest but directionally negative signal at these valuation levels. With no analyst consensus or price target data available in the enrichment to anchor an upside case, and the Goldman Healthcare Conference coming up as a potential re-rating event, the risk/reward favors fading the excitement rather than chasing it.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
2-3 weeks, into Goldman Healthcare Conference. Follow to be told when one lands.
Receipts
Google News — the original9:00 AM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →